Katharine Knobil - Net Worth and Insider Trading

Katharine Knobil Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Katharine Knobil owns 4 companies in total, including Kaleido Biosciences Inc (KLDO) , Arena Pharmaceuticals Inc (ARNA) , and Marker Therapeutics Inc (MRKR) among others .

Click here to see the complete history of Katharine Knobil’s form 4 insider trades.

Insider Ownership Summary of Katharine Knobil

Ticker	Comapny	Transaction Date	Type of Owner
KLDO	Kaleido Biosciences Inc	2019-02-27	See Remarks
ARNA	Arena Pharmaceuticals Inc	2020-06-12	director
MRKR	Marker Therapeutics Inc	2021-12-08	director
		2022-09-14	director

Katharine Knobil Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Katharine Knobil Ownership Network

Ownership Network List of Katharine Knobil

No Data

Ownership Network Relation of Katharine Knobil

Katharine Knobil Owned Company Details

What does Kaleido Biosciences Inc do?

Who are the key executives at Kaleido Biosciences Inc?

Katharine Knobil is the See Remarks of Kaleido Biosciences Inc. Other key executives at Kaleido Biosciences Inc include Chief Medical Officer Alison S Long , Chief Scientific Officer Van Hylckama Vlieg Johan , and 10 percent owner Flagship Ventures Fund Iv, L.p. .

Kaleido Biosciences Inc (KLDO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kaleido Biosciences Inc (KLDO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kaleido Biosciences Inc (KLDO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kaleido Biosciences Inc (KLDO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kaleido Biosciences Inc Insider Transactions

No Available Data

What does Arena Pharmaceuticals Inc do?

Who are the key executives at Arena Pharmaceuticals Inc?

Katharine Knobil is the director of Arena Pharmaceuticals Inc. Other key executives at Arena Pharmaceuticals Inc include director & President and CEO Amit Munshi , EVP & Chief Commercial Officer Robert Lisicki , and Executive VP and CBO Vincent Aurentz .

Arena Pharmaceuticals Inc (ARNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Arena Pharmaceuticals Inc (ARNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arena Pharmaceuticals Inc (ARNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Arena Pharmaceuticals Inc (ARNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arena Pharmaceuticals Inc Insider Transactions

No Available Data

What does Marker Therapeutics Inc do?

Who are the key executives at Marker Therapeutics Inc?

Katharine Knobil is the director of Marker Therapeutics Inc. Other key executives at Marker Therapeutics Inc include Interim CFO Eliot M Lurier , 10 percent owner Mohamad Makhzoumi , and 10 percent owner Carmen Chang .

Marker Therapeutics Inc (MRKR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Marker Therapeutics Inc (MRKR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Marker Therapeutics Inc (MRKR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Marker Therapeutics Inc (MRKR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Marker Therapeutics Inc Insider Transactions

No Available Data

What does Pliant Therapeutics Inc do?

Who are the key executives at Pliant Therapeutics Inc?

Katharine Knobil is the director of Pliant Therapeutics Inc. Other key executives at Pliant Therapeutics Inc include Chief Business Officer Hans Hull , Chief Medical Officer Eric Lefebvre , and Chief Financial Officer Keith Lamont Cummings .

Pliant Therapeutics Inc (PLRX) Insider Trades Summary

Over the past 18 months, Katharine Knobil made no insider transaction in Pliant Therapeutics Inc (PLRX). Other recent insider transactions involving Pliant Therapeutics Inc (PLRX) include a net sale of 405,422 shares made by Bernard Coulie , a net sale of 58,128 shares made by Mike Ouimette , and a net sale of 122,248 shares made by Eric Lefebvre .

In summary, during the past 3 months, insiders sold 0 shares of Pliant Therapeutics Inc (PLRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 745,379 shares of Pliant Therapeutics Inc (PLRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 745,379 shares.

Pliant Therapeutics Inc (PLRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pliant Therapeutics Inc Insider Transactions

No Available Data

Katharine Knobil Mailing Address

Above is the net worth, insider trading, and ownership report for Katharine Knobil. You might contact Katharine Knobil via mailing address: C/o Kaleido Biosciences, Inc., 65 Hayden Ave., Lexington Ma 02421.

Discussions on Katharine Knobil

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.